Neurocrine Biosciences Announces Publication Of Its KINCET-PRO Phase 4 Study Results Showing That Once-Daily INGREZZA Capsules Led To Substantial And Sustained Improvements In Patient-Reported Quality Of Life And Functionality
INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrating improvements in quality of life and functionality in people living with tardive dyskinesia across multiple
Neurocrine's medicine INGREZZA passed a big real-world study showing patients feel much better and can do more daily activities. When a company proves its medicine actually helps people's lives, that's something smart investors watch for as a sign of a strong product.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.